Advertisement

GLP-1s

Following jousts between Vermont Sen. Bernie Sanders and Novo Nordisk, the Senate Committee on Health, Education, Labor, and Pensions will vote June 18 on whether to subpoena the drugmaker's president about the cost of Ozempic and Wegovy. 

Advertisement

Gastric emptying is a critical component to most perioperative care instructions. Now with GLP-1 medications slowing gastric emptying purposefully, researchers are racing to understand how and if the new class of drugs affects surgical procedures. 

There are only two places in the world where semaglutide (Ozempic and Wegovy) is made, and Novo Nordisk is racing against time and high demand to increase supply, Bloomberg reported May 30. 

In a yearslong trial of more than 3,500 participants, Novo Nordisk's Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke and death.

Advertisement